CancerDrs

Lymphoma clinical trials in Wisconsin

50 actively recruiting lymphoma trials at 59 sites across Wisconsin.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06337318
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
  • Duluth Clinic Ashland — Ashland, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • University of Wisconsin Carbone Cancer Center - Johnson Creek — Johnson Creek, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
  • ProHealth D N Greenwald Center — Mukwonago, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …

Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Wisconsin:
  • Research Site — Madison, Wisconsin
  • Research Site — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…

Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Wisconsin:
  • Gunderson Health System — La Crosse, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…

Sponsor: University of Rochester
NCT ID: NCT05006482
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • HSHS Sacred Heart Hospital — Eau Claire, Wisconsin
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
  • Marshfield Medical Center-River Region at Stevens Point — Stevens Point, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…

Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell ly…

Sponsor: Corvus Pharmaceuticals, Inc.
NCT ID: NCT06561048
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treat…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091865
Sites in Wisconsin:
  • Prohealth Care Inc — Waukesha, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in Wisconsin:
  • Prohealth Care Inc — Waukesha, Wisconsin
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Margina…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06149286
Sites in Wisconsin:
  • Prohealth Care Inc — Waukesha, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Wisconsin:
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
  • Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutin…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04840602
Sites in Wisconsin:
  • ThedaCare Regional Cancer Center — Appleton, Wisconsin
  • Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
  • Gundersen Lutheran Medical Center — La Crosse, Wisconsin
  • Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
  • Marshfield Medical Center - Minocqua — Minocqua, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Wisconsin:
  • Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
  • Children's Hospital of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Wisconsin:
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
  • University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
  • Froedtert and MCW Moorland Reserve Health Center — New Berlin, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Wisconsin:
  • SSM Health Dean Medical Group ( Site 0106) — Madison, Wisconsin
  • Medical College of Wisconsin ( Site 0103) — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT05826535
Sites in Wisconsin:
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

DALY II USA/ MB-CART2019.1 for DLBCL

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts includ…

Sponsor: Miltenyi Biomedicine GmbH
NCT ID: NCT04792489
Sites in Wisconsin:
  • Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignan…

Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Wisconsin:
  • University of Wisconsin — Madison, Wisconsin
  • Medical College of Wisconsin — Milwaukee, Wisconsin
View on ClinicalTrials.gov →

Showing 25 of 50 trials with sites in Wisconsin. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09